USDR Company Profile

Very steep Decline at the company in the second quarter of 2023 earnings season

For the financial second quarter of 2023 company had turn a round to profits by presenting EPS of $0.53 per share compare to $-1.39 a year ago and EPS turned positive from $-1.75 per share from the prior financial reporting period.

Sales fell sharply by -79.223 % to $0.18 millions from $0.84 millions in the corresponding financial reporting period a year ago and sequentially Sales Tumbled by -49.052 % from $0.34 millions.

In the fourth quarter of 2022 earnings season LPCN Deficit has extended at $-0.04 per share, opposite of $-0.03 per share a year ago reporting season, In the prior reporting season The company realized $-0.04 per share.

Earnings down on soft Sales at in the fourth quarter of 2022

Sales and income went down in sympathy in the most recent fiscal period, where income fell by -18.63 % to $0.61 per share and revenue by -13.086 % year on year. Revenue were at $30.82 millions in contrast to $35.46 millions in the similar span a previous year.

Manhattan Bridge Capital Inc disclosed a very solid 42.453%, Sales surge, over the fiscal interval ending December 31 2022

For the October to December 31 2022 interval LOAN income per share increased by 5.71 % of $0.09 per share compare to $0.08 a year prior and profits fell by -18.81 % from $0.11 per share from the preceding quarter.

Sales jumped by 42.453 % to $2.23 millions from $1.57 millions in the similar quarter a year prior and sequentially Sales increased by 5.937 % from $2.11 millions.

The emerging entity from the Major Pharmaceutical Preparations industry the Cingulate Inc reported the fourth quarter of 2022 earnings season, earnings

The Major Pharmaceutical Preparations sector advisors begin to scrutinize the fourth quarter of 2022 earnings. Now those advisors monitor operating shortfall of $-4.475195 millions, from the CING, as it hasn't cited any top-line thus far, for the own October to December 31 2022 reporting period.